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A B S T R A C T
The misfolding and aggregation of alpha-synuclein (aSyn) are thought to be central events in synucleinopathies.
The physiological function of aSyn has been related to vesicle binding and trafficking, but the precise molecular
mechanisms leading to aSyn pathogenicity are still obscure. In cell models, aSyn does not readily aggregate, even
upon overexpression. Therefore, cellular models that enable the study of aSyn aggregation are essential tools for
our understanding of the molecular mechanisms that govern such processes. Here, we investigated the structural
features of SynT, an artificial variant of aSyn that has been widely used as a model of aggregation in mammalian
cell systems, since it is more prone to aggregation than aSyn. Using Nuclear Magnetic Resonance (NMR) spec-
troscopy we performed a detailed structural characterization of SynT through a systematic comparison with
normal, unmodified aSyn. Interestingly, we found that the conformations adopted by SynT resemble those de-
scribed for the unmodified protein, demonstrating the usefulness of SynT as a model for aSyn aggregation.
However, subtle differences were observed at the N-terminal region involving transient intra and/or inter-
molecular interactions that are known to regulate aSyn aggregation. Importantly, our results indicate that dis-
turbances in the N-terminal region of SynT, and the consequent decrease in membrane binding of the modified
protein, might contribute to the observed aggregation behavior of aSyn, and validate the use of SynT, one of the
few models of aSyn aggregation in cultured cells.
1. Introduction
Alpha Synuclein (aSyn) is an abundant, intrinsically disordered
protein mainly localized in presynaptic terminals. aSyn folds into am-
phipathic alpha-helices in the presence of negatively charged lipids and
can be divided into three distinct regions (Fig. 1A): the N-terminal re-
gion (residues 1–60), the central region (residues 61–95) originally
known as non-amyloid component (NAC) region, and the C-terminal
region (residues 96–140) [1,2]. The N-terminal region can adopt alpha-
helical structure when associated with phospholipid membranes [3,4].
The central region is highly hydrophobic and essential for aggregation
[5,6]. The C-terminal region is very acidic, is essential for the cha-
perone function of aSyn [7–9] and may modulate functions and inter-
actions of the protein in the cellular environment [10].
Although the biological function of aSyn is still unclear, increasing
evidence suggest it plays a major role in synaptic transmission and
synaptic plasticity [11], where it regulates the vesicle release upon
functional multimerization [12]. aSyn can misfold and accumulate in
amyloid deposits known as Lewy bodies (LBs) that are typical patho-
logical hallmarks in age-associated disorders named as
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synucleinopathies. These include Parkinson's Disease (PD), multiple
system atrophy, and Dementia with Lewy Bodies (DLB) [13–15].
aSyn aggregates are highly polymorphic, ranging from soluble oli-
gomeric forms to ring- or string-like oligomers, spherical-shaped pro-
tofibrils, and insoluble fibrils [16–18]. The precise correlation between
aSyn aggregation and neurotoxicity is unclear. aSyn fibrils seem to be
critical for disease spreading and exogenously added fibrils can seed
aSyn aggergation in cell models [19,20]. However, oligomeric forms of
aSyn are hypothesized to be the most cytotoxic forms of the protein,
rather than mature fibrillar aggregates [21–23]. To address this hy-
pothesis, it is important to use cell and animal models that recapitulate
central aspects of aSyn biology and aggregation. A commonly used cell-
based model enables the visualization of aSyn oligomers in living cells
via a bimolecular fluorescence complementation assay (BiFC) [24].
Currently, we lack models that mimic the process of formation of LB-
like inclusions in cells just based on the expression of wild type (WT)
aSyn. SynT, a modified form of aSyn displays a higher propensity to
aggregate and leads to the formation of inclusions that resemble LBs
upon co-expression with synphilin-1, a known aSyn-interacting protein
that is also present in LBs [25,26]. SynT consists of a modified form of
aSyn with a C-terminal extension, derived from the proteolytic cleavage
of enhanced green fluorescent protein (EGFP) (amino acids 1–83,
Fig. 1A), that makes aSyn more prone to aggregation. Thus, this pow-
erful and versatile system has been extensively used to model aSyn
aggregation in mammalian systems [27–33]. However, the C-terminal
extension may alter the biochemical and biophysical properties of aSyn
and, therefore, it is essential to characterize the molecular effects of this
extraneous amino acid sequence in SynT in order to demonstrate the
validity of the model. In this study, we used nuclear magnetic resonance
(NMR) to investigate the structural and dynamic features of SynT and to
demonstrate its usefulness and validity as a model of aSyn aggregation.
Interestingly, our results indicate that the conformations adopted by
Fig. 1. C-terminal modified aSyn (SynT)
forms inclusions in H4 cells. (A) Schematic
representation of the structure of human
aSyn highlighting the N-terminal (N-term),
NAC (NAC) and C-terminal (C-term) regions
of the protein. Amino acid residue numbers
are indicated for aSyn and for SynT. (B)
aSyn distribution in cells transfected with
aSyn, SynT and SynT+Synphilin-1. In cells
transfected with aSyn, or with aSyn +
Synphilin-1, aSyn is diffusely distributed
throughout the cell. In contrast, in cells
transfected with SynT, or with SynT +
Synphilin-1, aSyn forms inclusions of var-
ious sizes and morphologies. Cell nuclei
were labeled with DAPI and are artificially
colored in blue.
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aSyn in its SynT form resemble those of the unmodified protein. We
detected differences in the N-terminal region, likely involving transient
intra and/or intermolecular interactions. The steric hindrance at the C-
terminus and the altered transient interactions at the N-terminal region
of aSyn might be the factors behind the decreased membrane binding
capacity of SynT compared to the unmodified protein species.
Altogether, our work provides novel insights into the molecular de-
terminants of aSyn aggregation and demonstrates the relevance of using
SynT as a model for studying aSyn aggregation. Experimental strategies
that enable the analysis of aSyn aggregation are critical for the identi-
fication of anti-aggregation strategies that can form the basis of future
therapies for PD and other synucleinopathies.
2. Results
2.1. C-terminally-modified aSyn forms inclusions in cultured cells
As previously described, truncations and C-terminal modifications
of aSyn alter its propensity to aggregate [26,34]. We have used human
H4 neuroglioma cells, a widely used cell line to study cellular and
molecular aspects of various neurodegenerative diseases, in order to
investigate the effect of the C-terminal modification in aSyn (called
SynT) cytoplasmic inclusions [35]. Expression of SynT resulted in the
formation of cytosolic inclusions that exhibit LB-like properties [24,26]
(Fig. 1B, Fig. S1). Inclusion formation is potentiated by the co-expres-
sion of SynT together with synphilin-1, an interactor of aSyn that is also
present in LBs and Lewy neurites, as extensively described by several
groups [24,30,36]. In contrast, co-expression of untagged aSyn with
synphilin-1 did not result in the formation of discrete inclusions
(Fig. 1B), suggesting that modifications in the C-terminal region altered
the aggregation properties of aSyn.
2.2. Conformational and dynamic properties of the SynT variant
To analyze the impact that the C-terminal modification in SynT
might have on the structural features of aSyn, we used NMR spectro-
scopy to assess the conformational and dynamic features of the 15N
isotopically labeled recombinant aSyn and SynT proteins. Given that
the majority of aSyn in the cell is N-terminally acetylated, we used N-
terminally acetylated aSyn and SynT throughout our study (Anderson
2006, Ohrfelt 2011).
Prior to the NMR measurements, we analyzed the recombinant N-
terminally-acetylated SynT by SDS-PAGE and by gel-filtration chro-
matography to confirm the purity of the protein (Fig. S2 A-C). Then,
NMR spectroscopy of backbone amides in 15N-labeled SynT samples
demonstrated that the SynT protein remains intrinsically disordered
upon the C-terminal modification with the EGFP fragment. As expected,
backbone chemical shift changes were observed in a discrete number of
residues located in the vicinity of the EGFP fragment at the C-terminal
region of the aSyn protein (Fig. 2A). Interestingly, small but measurable
chemical shift changes became also evident in the region encompassing
amino acids 1–10 (Fig. 2A), well distant from the C-terminus. Thus, the
anchoring of the truncated EGFP segment at the C-terminus of aSyn in
the SynT variant affects the chemical shift of resonances belonging to
residues in both the C- and N-terminal region. Consistently, when the
SynT/aSyn intensity ratio of backbone amide resonances was measured,
a substantial reduction in the I/Io values was observed both at the N-
terminus and the C-terminal residues that are proximal to the EGFP
fragment (Fig. 2B). Interestingly, the degree of broadening of re-
sonances in the most affected residues in the N-terminal region were
almost similar to those observed at the C terminus. Finally, we observed
that resonances located at the NAC region were also affected, although
to a lesser extent.
These observations led us to evaluate the conformation of SynT and
its dynamic properties. First, we measured a nearly complete set of
3JHN-Hα couplings in both aSyn and SynT states, which are particularly
reliable quantitative reporters of the time-averaged distribution of the
backbone torsion angles ϕ39. The values measured for the two forms of
the protein are essentially indistinguishable, indicating that the C-
terminal modification with the EGFP fragment in the SynT form did not
influence substantially the local conformational propensities adopted
by untagged aSyn (Fig. 3A).
Next, we evaluated the backbone dynamics of SynT. To this pur-
pose, we measured 15N R1 and R2 relaxation rates and heteronuclear
(1H− 15N) nuclear Overhauser effects (hetNOEs). Whereas structures
persisting on supra-τc (τc= overall tumbling time) can be monitored by
chemical shifts and scalar coupling constants (J), 15N relaxation rates
and hetNOEs are sensitive to motions faster than the overall tumbling
time in the sub-nanosecond time regime. The set of 15N relaxation ex-
periments was firstly measured on aSyn, in which the relaxation para-
meters showed a similar sequence dependence, with lower values at the
termini of the protein and a plateau at the center of the relaxation
profile. In agreement with previous results [40], R1 values ranged be-
tween 1.3 and 1.7 s-1, R2 values between 2.0 and 3.5 s-1, and hetNOEs
values were found in the range 0 to −0.3 (Fig. 3B–D). The attachment
of the EGFP fragment to aSyn resulted in no significant changes in the
R1 and hetNOEs values, with the exception of the very terminal re-
sidues. However, pronounced deviations were observed for the R2 re-
laxation rates (Fig. 3C). Consistent with the broadening profile shown
in Fig. 2B, R2 rates were increased for the N-terminal half of the aSyn
sequence when the EGFP fragment was attached at the C-terminus,
which also experienced increased transverse relaxation. Whereas in-
creased R2 rates at the C-terminus can be connected to slower rotational
tumbling of the beta-structure containing EGFP fragment (Fig. 2B), the
faster transverse relaxation in the N-terminal half of the aSyn sequence
points to an exchange process likely driven by transient interactions
between the N-terminal region of aSyn and the EGFP fragment. No-
tably, higher R2 rates were centered at the Y39 residue, suggesting
contributions of aromatic interactions to the exchange process.
Overall, the results reported here allow us to conclude that the in-
trinsically disordered nature of aSyn is not strongly influenced by the C-
terminal modification in SynT, whereas the transient long-range con-
tacts between the N- and C-terminal regions reported for aSyn are
strengthened in the SynT variant.
2.3. Molecular interactions driven by the N-terminal region are affected in
the SynT variant
Since the N-terminal region of aSyn behaves as a key interface for
physiological or pathological processes such as membrane binding or
protein aggregation, we further investigated the influence of the EGFP
fragment on the N-terminal region of aSyn through the analysis of its
binding properties to lipids and small molecules with anti-amyloid ac-
tivity.
First, we analyzed the binding features of SynT to small unilamellar
vesicles (SUVs) with appropriate mixtures of DOPE, DOPC and DOPS
that have been shown to model the biochemical composition of sy-
naptic vesicles [38]. Although the slow tumbling rate of vesicles in-
duces lipid-bound aSyn to exhibit dynamic properties that hamper its
direct observation by solution NMR, exchange with the NMR-visible,
lipid-free form allows residue-specific access to the properties of the
membrane-bound state. We probed this exchange process using two-
dimensional 1He15N heteronuclear single quantum coherence (HSQC)
experiments of 100 μM aSyn in the presence of SUVs (1:100 protein-to-
lipid ratio). In line with previous studies, the NMR signal intensities of
the 100 N-terminal residues of aSyn were strongly decreased compared
with free aSyn (Fig. 4A). On the other hand, a smaller broadening effect
was observed for the N-terminal region of the SynT species in its
membrane-bound state, whereas its C-terminal region was more
strongly affected by lipid-binding when compared to aSyn. These re-
sults suggest that a different anchoring mechanism may exist for aSyn
and SynT binding to lipids.
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Finally, we used small molecules that bind exclusively to the N-
terminal region of aSyn as molecular probes to monitor the impact of
the EGFP fragment on the binding properties of the N-terminal inter-
face. To this purpose, we used the molecule phthalocyanine tetra-
sulfonate (PcTS). The exclusive binding of this molecule to the N-
terminal region of aSyn is regulated by the specific interaction of its
macrocycle ring with aromatic residues located at that region (F4 and
Y39), and by the electrostatic repulsions between the peripheral sul-
fonate groups in PcTS and the highly negatively charged C-terminal
region that is folded back toward the NAC domain in the monomeric
state of aSyn. As previously reported, PcTS binds preferentially to the
N-terminal region of aSyn (Fig. 4B). In contrast, this interaction is
abolished in the SynT variant, likely reflecting a change in the binding
behavior of the N-terminal region toward PCTs molecules. However,
the occurrence of a potential EGFP-PcTS interaction that sequesters
small molecules from its binding to the N-terminus of SynT cannot be
discarded at this point, and would have to be investigated in other
studies.
2.4. SynT does not form amyloid fibrils in vitro
Next, we investigated whether the EGFP fragment affected the fi-
brilization of aSyn in vitro, since it affects the aggregation of the protein
in cultured cells. Recombinant aSyn or SynT were incubated at 37 °C,
under constant agitation, and fibrillization kinetics were monitored by
Thioflavin T (ThT) binding. Surprisingly, SynT did not show any fibril-
specific increase in ThT intensity in vitro (Fig. 4C).
Amyloid fibril formation was further assessed by transmission
electron microscopy (TEM) analysis on negatively stained samples of
aSyn and of SynT, after the aggregation protocol. Consistently with the
ThT assay, we found that aSyn formed well-defined amyloid filaments
(Fig. 4D). In contrast, SynT formed non-fibrillar aggregates.
3. Discussion
aSyn is the major component of pathognomonic protein inclusions
in PD and other synucleinopathies, but the precise mechanisms un-
derlying aggregation and pathology are still elusive [39]. aSyn is a
paradigmatic example of an intrinsically disordered protein that is
capable of adopting a multitude of conformations, depending on the
environment where it occurs. For example, aSyn can exist as a soluble
cytosolic protein, membrane-bound, or aggregated [40–42]. In order to
understand the molecular determinants of aSyn aggregation, several in
vitro and in vivomodels have been employed, in an attempt to mimic the
behavior of the protein in synucleinopathies. However, while aSyn is
known to readily fibrilize in the test tube, it has not been possible to
consistently induce aSyn aggregation in cultured cells, just based upon
expression. To promote aSyn aggregation in cells, different strategies
have been employed, including co-expression with other proteins [43],
oxidative stress [44], metal ions [45,46], or the addition of extraneous
amino acid sequences [26,47]. An alternative strategy involves the
expression of an aSyn variant fused to a fragment of EGFP, thereby
changing the chemical properties of the C-terminal region of aSyn.
However, whether these manipulations mimic relevant aspects of aSyn
pathobiology, or simply represent artificial phenotypes that are not
accessible to the constellation of conformations aSyn can adopt remains
unclear. In the present study, we compared SynT with normal untagged
aSyn in terms of its folding and conformation. Our study clarifies the
aggregation behavior of SynT in cells and demonstrates that SynT is a
valid model of aSyn aggregation.
From a biophysical perspective, the NMR spectra and general dy-
namics of the protein backbone observed for aSyn and SynT demon-
strate that the aSyn part of SynT retains the intrinsically disordered
character of the untagged protein. However, we observed subtle
changes in the conformational propensities of the protein ensembles. As
expected, the C-terminal region of aSyn showed changes in the position
and intensities of the NMR signals, likely due to changes in the chemical
environment induced by the nearby EGFP fragment and its contribution
to the local rotational correlation time. On the other hand, we also
detected an attenuation of the intensity of the signal of the amide sig-
nals in the N-terminal region of SynT that correlated well with a che-
mical exchange process detected by 15 N spin relaxation measurements.
Taken together, these results suggest that the EGFP fragment might
transiently interact with the N-terminus of the protein in an inter- or
intra-molecular manner (Fig. 5). Intramolecular contacts between the
C– and N-Terminus have been described and were proposed to regulate
Fig. 2. NMR characterization of SynT. (A) Mean
weighted 1He15N chemical shift perturbation plot of
Ac-SynT versus Ac-aSyn. (B) Ac-SynT/Ac-aSyn NMR
signal intensity ratios. All NMR experiments were
recorded at 15 °C using 100 μM aSyn and SynT
samples dissolved in buffer B supplemented with
10% D2O.
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Fig. 3. Backbone dynamics of SynT. (A) 3J HN-Hα coupling constants measured for Ac-aSyn (blue) and Ac-SynT (red). (B,C) 15N relaxation rates of Ac-aSyn (blue)
and Ac-SynT (red). Panels (B) and (C) depict R1 and R2 rates, respectively. Panel (D) shows 1He15N hNOE profiles for both proteins. All experiments were recorded at
15 °C using Ac-aSyn (100 μM) and Ac-SynT (100 μM) dissolved in buffer B supplemented with 10% D2O.
C. Masaracchia, et al. BBA - Proteins and Proteomics 1868 (2020) 140298
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the major events of nucleation [40,48,49]. These long-range contacts
determine the “open” conformation of the molecule that allows ag-
gregation and alterations of these long-range contacts promotes ex-
posure of the fibrillating segment of the NAC region, hence enhancing
the aggregation propensity [49,50].
This transient interaction could explain the attenuated ability of the
N-terminal residues of SynT to interact with the small molecule PcTS
and could contribute to the altered binding mode of SynT with mem-
branes. Interestingly, it was previously shown that transient
interactions between C- and N-Terminus result in the formation of
compact aggregation-resistant structures [51]. We hypothesize that the
proximity of the tag could create steric disturbances that influence how
SynT interacts with membranes and folds into alpha-helical structures
on the membrane surface. Considering recent findings that indicate
aSyn aggregation is increased when aSyn is in its unstructured mono-
meric form, and is attenuated/blocked when it is in an alpha-helical
multimeric form associated with membranes [52], our results suggest
that the perturbed interaction of SynT with membranes might, at least
Fig. 4. Binding and aggregation properties of Ac-SynT.
Membrane binding properties of Ac-aSyn (Blue) and Ac-SynT (red) in the presence of artificial small unilamellar vesicles membranes (SUVs) [1:100 protein:SUVs
ratio] (A). Interaction profiles of the backbone amide groups of 10 μM Ac-aSyn, in blue and 90 μM Ac-SynT proteins, in red, in the presence of 50 μM of PcTS (B).
Continuous ThioT aggregation assays of a 25 μM solutions of Ac-aSyn (blue) and Ac-SynT (red). The proteins were diluted in Buffer A (25mM Tris, pH 7.7) (C). TEM
images of the resulting aggregates stained with uranyl acetate (scale bar, 500 nm) (D).
Fig. 5. Proposed mechanism for the structural properties of SynT. The EGFP fragment could transiently interact with the N-terminal region of the protein in an inter-
molecular or in an intra-molecular way. Overall, the general, chemical properties of aSyn are not affected by the tag, nor its propensity to maintain an intrinsically
disordered structure. Still, some of the physiological-related properties of aSyn appear to be affected by the tag (e.g., membrane binding properties and aggregation
propensities in vivo and in vitro).
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in part, be responsible for its increased aggregation propensity in cells.
Several studies have investigated the relationship between membrane
interactions and aSyn aggregation but, nevertheless, the mechanisms by
which lipids or lipid vesicles influence the aggregation of aSyn are still
not fully understood [53–56].
It has also been shown that the acidic C-terminal region of aSyn can
play a role and affect the aggregation properties of aSyn both in
monomeric and aggregated forms [10]. The aggregation kinetics are
sensitive to a wide range of ionic conditions [57], from weak C-terminal
charge shielding [10] to stronger charge modifications caused by the
presence of polycations [58] or metal ions [45,46,59,60], PTMs
[60,61], truncations [62,63] or, as in the case of our study, the addition
of tags [26]. Thus, it is possible that, due to the presence of the tag,
changes in the electrostatic environment of this region of the protein
may overall affect the aggregation behaviour.
Taken together our study indicates that the modification of the C-
terminus of aSyn in SynT, and the subsequent effect on the N-terminal
region, potentiates the ability of the protein to form intracellular in-
clusions, which recapitulates important molecular features of synu-
cleinopathies. Cellular models based on expression of aSyn variants
such as SynT are widely used tools for the identification of genetic and
pharmacological strategies to treat PD and other synucleinopathies.
Given the similarities observed between SynT and aSyn in terms of
folding and conformation, our study demonstrates the usefulness of
SynT as a model for aSyn aggregation.A detailed understanding of the
molecular mechanisms underlying aSyn aggregation, as afforded by the
SynT model, is important for the development of novel therapeutic
strategies for these devastating disorders.
4. Materials and methods
4.1. Human cell cultures
Human neuroglioma H4 cells were maintained at 37 °C and 5% CO2
environment, in Opti-Mem medium (PAN, Germany) supplemented
with 10% foetal calf serum (ThermoFisher) and 1% penicillin-strepto-
mycin (ThermoFisher). Cells were seeded in different well-plate for-
mats, one day prior to transfection, and kept up to 48 h after trans-
fection. Transfections were performed with calcium phosphate. Shortly,
3 h prior to transfection, fresh medium was added to the cells. DNA was
diluted in 1× HBS buffer with 25mM 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid, 140mM NaCl, 5 mM KCl, 0.75mM Na2HPO4
·2H2O, 6mM Dextrose, pH 7.1. After mixing, 2.5 M CaCl2 was added
dropwise and vigorously mixed. Followed 20min of incubation, the
mixture was added dropwise to the cells. Medium was replaced the next
morning. For total protein extraction, cells were lysed 48 h after
transfection in Radio-Immunoprecipitation Assay (RIPA) lysis buffer
(50mM Tris pH 8.0, 0.15M NaCl, 0.1% SDS, 1% NP40, 0.5% Na-
Deoxycholate, 2 mM EDTA and a Protease Inhibitor Cocktail (1 tablet/
10mL) (Roche Diagnostics, Mannheim, Germany)). The protein con-
centration was measured using a Bradford assay (BioRad Laboratories,
Hercules, CA, USA).
4.2. Immunocytochemistry
24 or 48 h after transfection, H4 cells were washed with PBS and
fixed with 4% paraformaldehyde (PFA) for 10min at room temperature
(RT), followed by a permeabilization step with 0.5% Triton X-100
(SigmaAldrich, St. Louis, MO, USA) for 10min at RT. After blocking in
10% normal goat serum (PAA, Cölbe, Germany)/DPBS for 1 h, cells
were incubated with primary antibody. Primary antibodies used were:
rabbit anti-aSyn (aSyn Antibody (C-20): sc-7011-R, 1:1000, Santa Cruz
Biotechnology, Dallas, USA) or mouse anti-V5 (v5 Mouse monoclonal
Antibody, R960–25, 1:1000, Invitrogen, Thermofisher), for 3 h or
overnight and secondary antibody (Alexa Fluor 488 donkey anti-mouse
IgG and/or Alexa Fluor 555 goat anti rabbit IgG, (Life Technologies-
Invitrogen, Carlsbad, CA, USA) for 2 h at RT. Finally, cells were stained
with Hoechst 33258 (Life Technologies- Invitrogen, Carlsbad, CA, USA)
(1:5000 in DPBS) for 5min, washed again and then fixed with Mowiol
for epifluorescence microscopy.
4.3. Protein purification
15N isotopically enriched and N-terminally acetylated aSyn and
SynT were obtained by transfecting E. coli BL21 competent cells with a
pET21 carrying the wild type aSyn gene or the SynT gene together with
a second plasmid encoding the components of yeast NatB acetylase
complex [64]. Plasmids carried different antibiotic resistance (ampi-
cillin and chloramphenicol) to select the doubly transformed E. coli
colonies. Both proteins were purified as previously reported [10].
Protein concentration was estimated from the absorbance at 274 nm
using an extinction coefficient of 5600M−1 cm−1 for aSyn, and of
16,055M−1 cm−1 for SynT. Protein acetylation was verified via mass
spectrometry.
4.4. Immunoblotting
40 μg of total protein from cell extracts was boiled for 10min at
100 °C in sample buffer (125mM of 1M Tris HCl pH 6.8, 4% SDS 0,5%
Bromphenol blue, 4 mM EDTA 20% Glycerol 10% β-Mercaptoethanol)
and subsequently separated by SDS-Page in a 15% polyacrylamide se-
paration gel and a 6% polyacrylamide stacking gel (Bio-Rad, Hercules,
CA, USA). Proteins were transferred to a nitrocellulose membrane using
a Mini Trans-Blot system (BioRad Laboratories, Hercules, CA, USA).
Western Blotting was performed using standard procedures. The fol-
lowing antibodies were used: anti-V5 (for detection of synphilin-1,
1:1000, Abcam, Boston, USA), anti-Syn1 (1:1000, BD Biosciences, San
Jose, CA, USA), anti a-Tubulin-1 (1:2000, SigmaAldrich, St. Louis, MO,
USA).
4.5. NMR experiments
All NMR spectra were recorded on Bruker 600MHz Avance III
spectrometer, equipped with a cryogenically cooled triple resonance 1H
(13C/15N) TCI probe. 1He15N SOFAST-HMQC [65], 1He15N HSQC, 15N
R1 and 15N R2 relaxation rates, 1He15N heteronuclear NOE and 3D
HNHA experiments were recorded at 15 °C using protein samples dis-
solved in buffer B (20mM MES, NaCl 100mM, pH 6.5) supplemented
with 10% D2O.
1He15N SOFAST-HMQC and 1He15N HSQC: we used 16 scans, 1024
complex points (sweep-width of 16 ppm in the 1H dimension) and 256
complex points (sweep-width of 26 ppm in the 15N dimension).
Sequence-specific assignments for the backbone of aSyn and SynT were
transferred from previously published work [59,66]. Only un-
ambiguously assigned, well resolved peaks were included in the ana-
lysis. The I/I0 ratios obtained for aSyn and SynT, in absence and pre-
sence of PcTS or SUVs were plotted as a function of the protein
sequence to obtain the intensity perturbation profiles [67]. Mean
weighted chemical shifts displacements (MWΔCS) for 1He15N were
calculated as as [(Δδ1H)2 + (Δδ15N/10)2]1/2.
15N R1 and R2 relaxation rates, and 1He15N NOE data were acquired
at 600MHz external field using previously described pulse sequences
[68]. Experiments were recorded with 1024 complex points and a
sweep width of 16 ppm for the 1H dimension, and 256 complex points
in the 15N dimension with a sweep width of 26 ppm. R1 and R2 re-
laxation rates were obtained by recording the experiments with dif-
ferent T1 and T2 relaxation delays. Resonance heights in the spectra at
each delay were fit to a two parameter exponential decay function to
obtain the rates. Steady-state 1He15N NOE (hetNOEs) values were ob-
tained from the ratio of peak heights in spectra collected with and
without an initial 4 s period of proton saturation during the recycling
delay.
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HN-Hα experiments were recorded with the following set up:
number of points, 1024 (1H), 80 (15N), 144 (1H); spectral width (ppm),
16 (1H), 26 (15N), 10 (1H); number of scans, 16. Three-bond HN-Hα
coupling constants (3J HN-Hα) were obtained from the ratio between
the intensities of the diagonal peaks and cross-peaks in the HN-Hα
correlation region [69]. Three-bond HN-Hα coupling constants (3J HN-
Hα) are sensitive to the torsion angle ϕ populated by each amide group
in the protein backbone reporting on secondary structure content. This
coupling falls in the range 3.0–6.0 Hz for an α-helix and 8.0–11.0 Hz for
a β-sheet structure. For a random-coil, a weighted average of these
values is observed, that typically ranges between 6.0 and 8.0 Hz for
most residues [70].
Acquisition and processing of NMR spectra were performed using
TOPSPIN 3.2 (Bruker Biospin). 2D spectra analyses were performed
with CCPN. For the 3J HN-Hα couplings calculation, the software CARA
was used. R1 and R2 relaxation data fitting was performed using CCPN
routines.
4.6. SUVs preparation
SUVs were prepared from a molar ratio of 1:1 of Coagulation
Reagent I containing DOPE:DOPS:DOPC (5:3:2 w/w) and DOPC (both
Avanti Polar Lipids Inc., USA) dissolved in chloroform yielding a final
molar ratio of DOPE:DOPS:DOPC (5:3:12 w/w). The lipid solution
formed a thin film under evaporation of the solvent with nitrogen gas
and was further dried by lyophilization under vacuum. The dried
phospholipids were dissolved in MES buffer (20mM MES, 100mM
NaCl, pH 6.5) and underwent several cycles of freeze-thawing and
water bath sonication until the solution became clear. The size dis-
tribution was also checked by DLS. For the NMR experiments a SUV
stock solution of 85mM (6.6% w/v) in respect to the monomers was
used.
4.7. Thioflavin T fluorescence assays
In vitro aggregation kinetics was obtained using a PolarStar OMEGA
microplate reader. The plate was shaken at 300 rpm/37 °C and fibril
formation was monitored by measuring Thioflavin-T (ThT) fluorescence
every 5min. The excitation wavelength was set to 440 nm and the Thio-
T emission was measured at 480 nm. Each well contained 150 μL of
25 μM AcaSyn or 25 μM AcSynT (Buffer A), 1 μM Thio-T, and a 2mm
glass bead to accelerate fibrillation. In all cases, the reported values
correspond to the average of five independent aggregation measure-
ments.
4.8. Transmission electron Microscopy
Samples were shaken at 300 rpm/37 °C for 3 days, adsorbed onto
carbon-coated grids, rinsed with water, and stained with 2% (wt/vol)
uranyl acetate. The samples were exhaustively scanned and re-
presentative fields were imaged in a Hitachi H-7000 TEM operating at
an accelerating voltage of 75 kV.
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